Hong Kong Baptist University

Sanwa Kagaku Kenkyusho Co., Ltd.

Stephen Chung

Sookja Kim Chung

Chihiro Hibi

Shiqing Zhang

The present disclosure relates to, inter alia, a method of treating cancer in a human patient in need thereof, comprising administering a therapeutically effective amount of a substrate of AKR1B1, AKR1B10, or both to said patient, wherein said patient has, or is suspected to have, cancer cells with elevated levels of AKR1B1, AKR1B10, or both, wherein said substrate is not 2-deoxy-D-glucose.

Method of using substrates of AKR1B1/AKR1B10 as anti-cancer drugs

The present invention provides a protective agent for retinal nerve or optic nerve which exerts its effect through a different mechanism from that of conventional therapeutic agents and can be taken for long periods. The present invention is the protective agent for retinal nerve or optic nerve which comprises a compound with aldose reductase inhibiting activity such as the compound represented by the following general formula as an active ingredient. A preferable compound thereof is (2S,4S)-6-fluoro-2',5&#x2032;-dioxospiro[chroman-4,4&#x2032;-imidazolidine]-2-carboxamide: wherein X represents a halogen atom or a hydrogen atom, R1 and R2 independently represent a hydrogen atom or an optionally substituted C1 to C6 alkyl group, or Rand R, together with a nitrogen atom bound thereto, or optionally another nitrogen atom or an oxygen atom, are combined to form a 5- to 6-membered heterocycle.

Growing community of inventors

Hong Kong, China

Stephen Chung